Sanofi interest in making a big acquisition has been clear for the last few years and its struggles to solidify such desire into concrete results have often been commented upon; twice it has been beaten to the punch by fellow big pharma companies, with Pfizer snagging Medivation in 2016 and Johnson & Johnson offering a more attractive deal to acquire Actelion in 2017.
This time round, the company hasn’t been thwarted by the competition and has announced the successful conclusion of a $11.6 billion deal to acquire Bioverativ.
